Clinical trials: asthma
Proctitis, Proctosigmoiditis
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who…
- Trial name
- NCT01008410
- Testing
- Budesonide
- Where
- 63 sites in United States
- Volunteers
- 265 people
- Sponsor
- Bausch Health Americas, Inc.
Asthma
A Dose-ranging Study of Fluticasone Furoate (FF)
This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma.
- Trial name
- NCT01563029
- Testing
- Fluticasone Furoate, Fluticasone Propionate
- Where
- 139 sites in United States, Bulgaria and 13 more
- Volunteers
- 597 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium…
- Trial name
- NCT01311661
- Testing
- Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily
- Where
- 36 sites in United States, Austria and 4 more
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults
To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.
- Trial name
- NCT00968669
- Testing
- MEDI528 30 mg, MEDI528 100 mg, MEDI528 300 mg
- Where
- 57 sites in United States, Argentina and 8 more
- Volunteers
- 329 people
- Sponsor
- MedImmune LLC
Allergic Rhinitis, Asthma
Randomized Evaluation of Ten Allergy Skin Prick Test Devices
The goal of this study is to compare ten current and readily available FDA approved allergy skin prick devices to determine the most sensitive and specific product and methods used for the diagnosis of allergic disease.
- Conditions
- Allergic Rhinitis, Asthma, Food Allergy, Skin Testing
- Trial name
- NCT03509766
- Testing
- Histamine skin testing
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Asthma
Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler
This study aims to explore the potential impact of switching inhalers by assessing the handling error rate (critical and non-critical) in controlled asthmatics currently treated with, and using correctly, SERETIDE via the DISKUS…
- Trial name
- NCT02416180
- Testing
- SERETIDE MDI
- Where
- 7 sites in Germany
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
Asthma
Utilizing CT Based Imaging Parameters of Body Composition to Understand Heterogeneity of Response to Biologic Therapies in Severe Asthma Cohorts
This study will utilize University of Michigan EMR data to form a retrospective cohort of severe asthma patients on biologic therapies for asthma with computed tomography (CT) imaging and known outcomes on therapy.
- Trial name
- NCT06922760
- Where
- 2 sites in United States
- Volunteers
- 233 people
- Sponsor
- University of Michigan
Asthma
Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia
The purpose of this study is to compare whether Symbicort Maintenance \& Reliever Therapy (SMART) is more effective in uncontrolled asthmatic patients than their current therapy in a real life situation.
- Trial name
- SMARTASIA (NCT00939341)
- Testing
- Symbicort (Budesonide/Formoterol)
- Where
- 35 sites in China, India and 3 more
- Volunteers
- 862 people
- Sponsor
- AstraZeneca
Bronchial Asthma
Effect of High Dose Ciclesonide on Asthma Control
The aim of the trial is to investigate asthma control with 160 to 640 mcg ciclesonide/day. Asthma control will be assessed by the Asthma Control Questionnaire (ACQ).
- Trial name
- CONTRAST (NCT01455194)
- Testing
- Ciclesonide
- Where
- 30 sites in Argentina, Brazil and 3 more
- Volunteers
- 520 people
- Sponsor
- AstraZeneca
Severe Uncontrolled Asthma
PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
This study will evaluate the PK, PD and long-term safety of Benralizumab administered subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma.
- Trial name
- TATE (NCT04305405)
- Testing
- Benralizumab
- Where
- 15 sites in United States, Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Asthma
GSNOR Phenotyping/GSNO Challenge in Severe Asthma
Asthma is caused by or worsened by different things in different people. It is because of these differences that not all people with asthma respond the same to all treatments and medicines.
- Trial name
- NCT03926741
- Testing
- GSNO Challenge
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- James Reynolds
Asthma
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: To evaluate the safety and tolerability of dupilumab.
- Trial name
- NCT02414854
- Testing
- Dupilumab, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol
- Where
- 389 sites in United States, Argentina and 20 more
- Volunteers
- 1,902 people
- Sponsor
- Sanofi
Severe Asthma, Moderate or Severe Major Depressive Disorder
Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD).
- Trial name
- NCT00621946
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy…
- Trial name
- NCT01277523
- Testing
- tiotropium high dose, tiotropium low dose
- Where
- 69 sites in United States, Argentina and 12 more
- Volunteers
- 392 people
- Sponsor
- Boehringer Ingelheim
Asthma
The Use of Rosiglitazone to Treat Asthma
Asthma is a common chronic disease characterized by airway inflammation and bronchoconstriction. This study utilizes the drug rosiglitazone (Avandia)to treat the effects of airway inflammation in patients with asthma.
- Trial name
- NCT00614874
- Testing
- rosiglitazone
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Creighton University
Asthma
Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients
The primary objective of the study is to show similarity of efficacy on Pulmicort Respules 1.0 mg/day or 2.0 mg/day for 6 weeks in the treatment period and the corresponding doses of Pulmicort Turbuhaler 400 μg/day or 800 μg/day…
- Trial name
- NCT00855959
- Testing
- Budesonide, Pulmicort Turbuhaler
- Where
- 6 sites in Japan
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Lower Respiratory Tract Infection (LRTI)
Procalcitonin Antibiotic Consensus Trial (ProACT)
The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory…
- Trial name
- ProACT (NCT02130986)
- Testing
- Procalcitonin level, Results of procalcitonin (PCT) level to treating clinician, Provide procalcitonin guideline to treating clinician
- Where
- 13 sites in United States
- Volunteers
- 1,664 people
- Sponsor
- University of Pittsburgh
Asthma
Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Primary objective To show the superiority of CHF 1535 (BDP/FF) pMDI (800/24 μg per day) over BDP HFA pMDI (800 μg per day) in terms of change from baseline to the entire treatment period in average pre-dose morning peak…
- Trial name
- FORCE (NCT01577082)
- Testing
- CHF1535 200/6 µg pMDI, BDP HFA 100 µg pMDI
- Where
- 66 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 542 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years…
- Trial name
- MITCHELL (NCT06644924)
- Testing
- Intervention: AS MDI, Intervention: Ventolin Evohaler
- Where
- 22 sites in United States
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.